Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 309-322 , August 2010

New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatment

References 

  1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239–243
  2. Choi CM, Lerner EA. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc. 2001;6:175–182
  3. Hsia R. Leishmaniasis. Available from: URL:http://www.emedicine.com/emerg/topic296.htm. Accessed on March 23, 2009.
  4. Centers for Disease Control and Prevention (CDC). The yellow book, health information for travelers, CDC 2010. Available at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leishmaniasis.aspx. Accessed February 8, 2010.
  5. David C, Dimier-David L, Vargas F, Torrez M, Dedet JP. Fifteen years of cutaneous mucocutaneous leishmaniasis in Bolivia: a retrospective study. Trans R Soc Trop Med Hyg. 1993;87:7–9
  6. Lessa MM, Lessa HA, Castro TW, Oliveira A, Scherifer A, Machado P, et al. Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol. 2007;73:843–847
  7. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica. 2000;16:925–950
  8. Jorquera A, Ledezma E, De Sousa L, Garcia A, Sanchez J, Zerpa J, et al. Epidemiologic characterization of American cutaneous leishmaniasis in an endemic region of eastern Venezuela. Am J Trop Med Hyg. 1998;58:589–593
  9. McHugh CP. Leishmaniasis in Washington County. Texas. J Am Acad Dermatol. 2002;47:614–616
  10. Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol. 2008;58:650–652
  11. Ghosn SH, Kurban AK. In:  Wolff K,  Goldsmith LA,  Katz SI,  Gilchrest BA,  Paller AS,  Leffell DJ editor. Fitzpatrick's dermatology in general medicine. 7th ed. Leishmaniasis and other protozoan infections. Vol 11:New York, NY: McGraw Hill Inc; 2008;p. 2001–2009
  12. Beenal KR, Ramesh V, Mukherjee A. Identification of parasite antigen, correlation of parasite density and inflammation in skin lesions of post kala-azar dermal leishmaniasis. J Cutan Pathol. 2003;30:616–620
  13. Courret N, Lang T, Milon G, Antoine JC. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different processes and status protection in BALB/c mice. Int J Parasitol. 2003;33:1373–1383
  14. Schwartz E, Cristoph H, Blum J. New World cutaneous leishmaniasis in travelers. Lancet Infect Dis. 2006;6:342–349
  15. Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, et al. New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travelers. QJM. 2004;97:781–788
  16. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191–1199
  17. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50–54
  18. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111–126
  19. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis. 2008;46:223–231
  20. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (viannia) infection. J Infect Dis. 2006;193:1375–1383
  21. Alkhwajah A. Recent trends in the treatment of cutaneous leishmaniasis. Ann Saudi Med. 1998;18:412–416
  22. Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al. A double blind, randomized placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis. 2006;43:161–167
  23. Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM. 2000;93:733–737
  24. Osorio LE, Palacios R, Chica ME, Ochoa MT. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet. 1998;351:498–499
  25. Guena MFV, Marsden PD, Cuba CC, Barreto AC. Further trials of nifurtimox in mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1981;75:335–337
  26. Vasquez RE, Soong L. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect Immun. 2006;74:6769–6777
  27. Anjili C, Langat B, Ngumbi P, Mbati PA, Githure J, Tonui WK. Effects of anti- Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae). East Afr Med J. 2006;83:72–78
  28. Zhai L, Chen M, Blom J, Theander TG, Christensen SB, Kharazmi A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother. 1999;43:793–803
  29. Akilov OE, Kosaka S, O'Riordan K, Hasan T. Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem Photobiol Sci. 2007;6:1067–1075
  30. Claes DE, Clemens F, Flory J, Abedelmajeed N, Arieh I, Charles JL, et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol. 2003;139:432–434
  31. The Sanger Centre. Sequencing projects. Available from: URL:http://www.sanger.ac.uk/Projects/. Accessed March 25, 2009.
  32. Myler PJ, Fasel N. Leishmania: after the genome. 1st ed.. Norfolk, UK: Caister Academic Press; 2008;
  33. Wyler DJ, Marsden PD. Leishmaniasis. In:  Warren KS,  Mahmoud AAF editor. Tropical and geographical medicine. New York: McGraw-Hill Book Co; 1984;p. 270–280
  34. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296–306
  35. Berman JD. Treatment of New World cutaneous and mucosal leishmaniasis. Clin Dermatol. 1996;14:519–522
  36. Navin TR, Arana BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992;165:528–534
  37. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005;72:133–137
  38. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travelers. J Antimicrob Chemother. 2004;53:158–166
  39. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5:150–158
  40. Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM. Management of cutaneous leishmaniasis in adults and children. Med Trop (Mars). 2005;65:487–495
  41. Nacher M, Carme B, Sainte Marie D, Couppie P, Clyti E, Guibert P, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331–336
  42. Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002;35:261–267
  43. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis. 1994;18:381–384
  44. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg. 1997;57:651–655
  45. Oliveira-Neto MP, Mattos Mda S. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. Rev Soc Bras Med Trop. 2006;39:323–326
  46. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol. 1997;45:496–499
  47. Oliveira-Neto MP, Schubach A, Araujo ML, Pirmez C. High and low doses of antimony (Sbv) in American cutaneous leishmaniasis: a five years follow-up study of 15 patients. Mem Inst Oswaldo Cruz. 1996;91:207–209
  48. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy on American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil–an area of Leishmania (V.) braziliensis transmission. Int J Dermatol. 1997;36:463–468
  49. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg. 1994;50:107–111
  50. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis. 1993;16:417–425
  51. Morelli P, Gianelli E, Calattini S, Corbellino M, Antinori S, Meroni L. Itraconazole can be effective in the treatment of sporotrichoid leishmaniasis. J Travel Med. 2004;11:328–330
  52. Jolliffe DS. Cutaneous leishmaniasis from Belize–treatment with ketoconazole. Clin Exp Dermatol. 1986;11:62–68
  53. Dan M, Verner E, El-on J, Zuckerman F, Michaeli D. Failure of oral ketoconazole to cure cutaneous ulcers caused by Leishmania braziliensis. Cutis. 1986;38:198–199
  54. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990;89:147–155
  55. Davis AJ, Kedzierski L. Recent advances in antileishmanial drug development. Curr Opin Invest Drugs. 2005;6:163–169
  56. El-On J, Cawich F, Evans DA, Weinrauch L. Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana. Int J Parasitol. 1993;23:121–127
  57. Andrade-Narvaez FJ, Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG. Clinical picture of cutaneous leishmaniasis due to Leishmania(Leishmania) mexicana in the Yucatan peninsula, Mexico. Mem Inst Oswaldo Cruz. 2001;96:163–167
  58. El-on J, Messer G. Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am J Trop Hyg. 1986;35:1110–1116
  59. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of tropical treatment of methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. 2001;65:466–470
  60. Neva FA, Ponce C, Ponce E, Kreutzer R, Modabber F, Olliaro P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg. 1997;91:473–475
  61. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 2004;91:153–160
  62. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis. 1998;26:56–58
  63. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimoniate. Clin Infect Dis. 1995;20:47–51
  64. Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin. J Parasitol. 1999;85:354–359
  65. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg. 2002;66:147–151
  66. Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612–616
  67. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315–317
  68. Brown M, Noursadeghi M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203–205
  69. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkylphosphocholines and related derivatives against Leishmania donovani. Biochem Pharmacol. 1987;36:2633–2636
  70. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecyl phosphocholine; oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992;36:1630–1634
  71. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266–1272
  72. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(Suppl):S26–S33
  73. Simeen BR, Bari AU, Nadeem M. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak. 2007;17:132–135
  74. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2008;78:210–211
  75. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg. 2006;100(Suppl):S34–S40
  76. Soto JT, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis. 2001;33:E57–E61
  77. Najarian DJ, English JC. Imiquimod cream: a new multipurpose topical therapy for dermatology. Pharmacy & Therapeutics. 2003;28:122–126
  78. Wagner TL, Horton VL, Carlson GL, Myhre PE, Gibson SJ, Imbertson LM, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 1997;9:837–845
  79. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunoregulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis. 1999;179:1485–1494
  80. Miranda-Verastegui C, Llianos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis. 2005;40:1395–1403
  81. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis. 2001;33:1847–1851
  82. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis. 2007;44:1549–1554
  83. Pfaller MA, Marr JJ. Antileishmanial effect of allopurinol. Antimicrob Agents Chemother. 1974;5:469–472
  84. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis. 1997;24:165–169
  85. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med. 1992;326:741–744
  86. Guderian RH, Chico ME, Rogers MD, Pattishal KM, Grogi M, Berman JD. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg. 1991;45:92–97
  87. Saenz RE, Paz HM, Johnson CM, Marr JJ, Nelson DJ, Pattishall KH, et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis. 1989;160:153–158
  88. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med. 1997;126:232–236
  89. Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In:  Guerrant RL,  Walker DH,  Weller PF editor. Tropical infectious diseases: principles, pathogens and practice. 2nd ed.. Philadelphia: Churchill Livingstone; 2006;p. 1095
  90. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine. 2008;26:1709–1724
  91. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006;123:423–438
  92. Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Fowell DJ, et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol. 2000;165:915–924
  93. Selvapandiyan A, Duncan R, Debrabant A, Lee N, Sreenivas G, Salotra P, et al. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res. 2006;123:455–466
  94. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Annu Rev Immunol. 2000;18:927–974
  95. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol. 2002;168:3992–4000
  96. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med. 2002;195:1565–1573
  97. Reed SG. Leishmaniasis vaccination: targeting the source of infection. J Exp Med. 2001;194:F7–F9
  98. Grimaldi G, Tesh RB. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev. 1993;6:230–250
  99. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002;359:2188–2194
  100. Yamey G. The world's most neglected diseases. BMJ. 2002;325:176–177
  101. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol. 1995;89(Suppl):83–88
  102. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis. 2008;14:1013–1018
  103. Chaves LF, Pascual M. Climate cycles and forecasts of cutaneous leishmaniasis, a nonstationary vector-borne disease. PLoS Med. 2006;3:e295
  104. World Health Organization. Leishmaniasis and Leishmania/HIV co-infection. WHO report on global surveillance of epidemic-prone infectious diseases. Available at: http://www.who.int/csr/resources/publications/surveillance/Leishmaniasis.pdf. Accessed February 7, 2010.
  105. Bogdan C, Schönian G, Bañuls AL, Hide M, Pratlong F, Lorenz E, et al. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis. 2001;32:302–306
  106. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health. 2008;13:256–264

 Funding sources: None.

 Conflicts of interest: None declared.

PII: S0190-9622(09)01148-7

doi: 10.1016/j.jaad.2009.06.088

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 309-322 , August 2010

Article Tools